Lyra Therapeutics, Inc.LYRANASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank0
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P0
Near historical low
vs 5Y Ago
-0.1x
Contraction
Streak
3 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2024 | -8.88% |
| 2023 | 23.80% |
| 2022 | 30.66% |
| 2021 | 137.13% |
| 2020 | 4.07% |
| 2019 | 141.85% |
| 2018 | 0.00% |